International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 138-144 www.ijprajournal.com ISSN: 2456-4494

Descriptive Study on Guillain Barré Syndrome

Ritesh B. Andhale[1], Kiran J. Pawara[1], Vikas S. Chaudhari[1], Hemant P. Suryawanshi[1*], R.A. Ahirrao

[1]*P. G. College of Pharmaceutical Science and Research, Chaupale, Dist. Nandurbar*

Date of Submission: 05-07-2025 Date of Acceptance: 15-07-2025

ABSTRACT: Guillain-Barré Syndrome (GBS) is an acute, immune-mediated poly radiculo neuropathy that primarily affects the peripheral nervous system. It often presents with rapidly progressing muscle weakness, areflexia, and, in severe cases, respiratory failure. The syndrome is commonly preceded by an infection, such as Campylobacter jejuni, and is believed to result from molecular mimicry, where the immune response to the infection cross-reacts with peripheral nerve components. Diagnosis is primarily clinical, supported by cerebrospinal fluid analysis and nerve conduction studies. Treatment typically includes intravenous immunoglobulin (IVIG) or plasmapheresis, with most patients showing significant recovery over time. Early diagnosis and prompt management are crucial in reducing morbidity and mortality. This review highlights the pathophysiology, clinical features, diagnosis, and current treatment strategies of GBS.

KEYWORDS: Autoimmune neuropathy, acute flaccid paralysis, plasmapheresis, demyelination, Campylobacter jejuni.

I. INTRODUCTION:

Guillain-Barré Syndrome (GBS) is a rare but serious autoimmune neurological disorder in which the body's immune system mistakenly attacks the peripheral nervous system. The peripheral nerves play a crucial role in transmitting signals between the brain, spinal cord, and the rest of the body. Damage to these nerves results in muscle weakness, numbness, and, in severe cases, paralysis. The exact cause of GBS is not fully understood, but it is often preceded by a viral or bacterial infection, such as respiratory infections or gastrointestinal infections caused by Campylobacter jejuni. In some cases, GBS has also been linked to vaccinations and surgical procedures, although these associations are rare. The disorder can affect individuals of any age, but it is more common in adults and males. GBS manifests in various forms, with the most common being Acute Inflammatory Demyelinating Polyneuropathy (AIDP), which primarily affects the myelin sheath of the peripheral nerves, leading to muscle weakness that starts in the legs and spread supwards. Other variants include Miller Fisher Syndrome (MFS), which affects eye movements and coordination, and Acute Motor Axonal Neuropathy (AMAN), which predominantly involves motor nerve damage. Since GBS is a rapidly progressing condition, early diagnosis and medical intervention are crucial to prevent severe complications, such as respiratory failure. While there is no definitive cure, treatments like plasmapheresis (plasma exchange) and intravenous immunoglobulin (IVIG) help manage symptoms and accelerate recovery. Most patients recover fully within months to a year, though some may experience long-term weakness or neurological issues.[1-5]

II. PATHOPHYSIOLOGY:

Immune System Dysfunction and Autoantibody Production GBS involves an aberrant immune response to an external trigger, leading to cross-reactivity between microbial antigens and neural components due to molecular mimicry. Molecular Mimicry: Infections like Campylobacter jejuni, Cytomegalovirus, and Epstein-Barr virus produce antigens similar to gangliosides in neurons. The immune system, while attacking the pathogen, produces auto antibodies against myelin sheath or axonal membranes. Role of T cells and B cells: Activated T helper cells release inflammatory cytokines (IL-2, IL-6, TNF-alpha, IFN- gamma), promoting B-cell activation. B cells produce auto antibodies, initiating nerve damage. Complement Activation and Inflammatory Damage Auto antibodies binding to gangliosides activate the complement system, forming the membrane attack. complex (MAC), leading to: Demyelination - Schwann cell and myelin destruction. Axonal Injury - Severe cases involve axonal degeneration. Macrophage Infiltration - Further nerve function impairment.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 138-144 www.ijprajournal.com ISSN: 2456-4494

2.1 Types of Nerve Damage In GBS:

GBS has several pathological sub types:

Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Most common, involving immune-mediated demyelination and slow nerve conduction. Acute Motor Axonal Neuropathy (AMAN): More common in Asia and Latin America, linked to anti-GM1 antibodies. Acute Motor-Sensory Axonal Neuropathy (AMSAN): Severe axonal damage affecting motor and sensory neurons. Miller-Fisher Syndrome (MFS): Rare, involving cranial nerves and characterized by ophthalmoplegia, ataxia, and are flexia. Disruption of Nerve Conduction and Clinical Consequences Motor Dysfunction: Progressive ascending paralysis, weakness in arms and respiratory muscles. Sensory Dysfunction: Tingling, numbness, loss of deep tendon reflexes (areflexia).Autonomic Dysfunction: Blood pressure fluctuations, irregular heart rate.

Respiratory Failure: Paralysis of the diaphragm in severe cases. Recovery and Nerve Regeneration In demyelinating cases, Schwann cells initiate remyelination fogradual recovery. In axonal forms, recovery depends on axonal regrowth. Physical therapy and rehabilitation play a crucial role.[6-8]

III. EPIDEMIOLOGY:

Incidence and Prevalence Global Incidence:

Approximately 1 to 2 cases per 100,000 people per year. Regional Variation: North America& Europe: 1.1 1.8 cases per 100,000/year Asia: 0.4-1.7 cases per 100,000/year Africa & South America: Limited data, but rates may be slightly higher. Prevalence: GBS is rare, as most cases recover or do not survive.

Age and Gender Distribution Age:

More common in adults, with higher incidence in individuals over 50. Gender: Males are affected 1.5 times more than females.

Seasonal and Geographic Variations Seasonal Trends:

Cases peak in late summer and early autumn. Geographic Factors: More common in developed countries; higher cases in tropical areas due to infections like Campylobacterjejuni.

Risk Factors and Associated Conditions Infections:

Campylobacterjejuni: Foundin~40%-70%ofcases. i nfluenza, Mycoplasma pneumoniae, Epstein-Barr virus, and CMV.

Vaccination: Slight risk increases post-influenza vaccination (~1-2 cases per milliondoses), butrisk from infection is higher.

Other Factors: Surgery, trauma, pregnancy, and auto immune diseases.

Mortality and Prognosis Mortality Rate:3%-7% of patients die due to complications. Eighty percent recover completely or with only mild residual weakness. About 20% to 30% of severe cases call for mechanical ventilation. Epidemiological Trends Over Time Incidence has remained stable over the decades. COVID- 19 pandemic linked to possible increased cases, but no strong causal link.[9-11]

IV. PHARMACOLOGY:

Pharmacokinetics in GBS Treatment

Absorption: IVIG and plasma exchange do not require absorption as they are directly administered into the bloodstream. Oral drugs like gabapentin and pregabalin have variable absorption depending on gastrointestinal conditions.

Distribution: IVIG remains in plasma with limited distribution to tissues. Corticosteroids are widely distributed, including into muscle and the nervous system.

Metabolism: IVIG is metabolized into amino acids in the reticuloend othelial system. Corticosteroids undergo hepatic metabolism via CYP3A4. Gabapentin and pregabalin are minimally metabolized**.**

Elimination & Excretion: IVIG is degraded and excreted by the kidneys. Corticosteroids' inactive metabolites are excreted via urine. The majority of gabapentin and pregabalin are eliminated unaltered in the urine. Pharmacodynamics in GBS

IVIG: Blocks auto antibodies, modulates immune response, and reduces inflammation.

Plasmapheresis: Directly removes harmful antibodies from circulation.

Corticosteroids: Suppress immune activation, reducing inflammation.

Gabapentin/ Pregabalin: Reduce excitatory neurotransmitter release, relieving neuropathic pain.

Heparin: In hibits clot formation by enhancing antithrombin III activity.[12-14]

V. SIGN AND SYMPTOMS:

Early Symptom s(Initial1-3Days)

Paresthesia-related tingling sensations include prickly or "pins-and-needles" feelings in the ankles, toes, and fingers.

Weakness in muscles: usually begins in the legs

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 138-144 www.ijprajournal.com ISSN: 2456-4494

and moves up. Leg instability is the sensation of weakness or unsteadiness when walking.
Inflammation of the nerve roots causes a deep, aching pain in the lower back.
Fatigue: Generalized weakness and exhaustion.
Progressive Symptoms (First Few Weeks, Peak by 2-4 Weeks)
Ascending weakness: Weakness starts in the legs, spreads to the arms, and can affect the face. Loss of deep tendon reflexes (Areflexia): Reflexes (such as knee-jerk reflex) are absent.
Difficulty in walking: May need assistance or become unable to walk. Loss of coordination
(Ataxia): Affected individuals struggle with precise movements.
Severe Symptoms (Medical Emergency, Peak at 4 Weeks)

Complete paralysis:
Some patients may be come unable to move at all.
Severepain: Persistent nerve pain may require strong painkillers.
Heart rhythm abnormalities: Irregular heartbeat due to autonomic dysfunction.
Coma or organ failure (in rare cases): If left untreated, severe autonomic dysfunction can lead to life-threat.
Recovery Phase (Weeks to Months, Sometimes Years)

Gradual improvement:
Weakness and sensation loss beg into recover.
Slow nerve regeneration: Damaged nerves take time to heal (sometimes months to years).
Residual symptoms: Weakness, exhaustion, or pain may persist for some patients.
Risk of recurrence: Rarely, GBS can relapse, requiring additional treatment.
Special Variants of GBS (Different Symptom Presentations)
Miller Fisher Syndrome (MFS): Absence of reflexes, loss of coordination, and paralysis of the eye muscles. Acute Motor Axonal Neuropathy (AMAN) Severe muscle weakness, especially in limbs.[15-18]

VI. CAUSES AND FACTORS RESPONSIBLE FOR GUILLAIN-BARRÉ SYNDROME:

Infections as a Trigger for GBS:

Guillain-Barre Syndrome (GBS) is primarily triggered by infections, which stimulate an abnormal immune response.GBS has been linked to a number of bacterial and viral infections, including:

Campylobacterjejuni Infection:

One of the most common infections linked to GBS. A bacterium called Campylobacter jejuni can be found in tainted food and water. It results in gastroenteritis, which causes fever, diarrhoea, and pain in the abdomen. The immune system's response to the infection may mistakenly attack nerve cells due to molecular mimicry, where bacterial antigens resemble nerve gangliosides. Acute Motor Axonal Neuropathy, or AMAN, is the axonal variant of GBS that is closely linked to Campylobacter jejuni infection.

Viral Infections:
Numerous viral infections have been identified as GBS triggers:
Influenza virus:

Seasonal flu and its vaccination have been rarely associated with GBS. Cytomegalovirus (CMV): A type of herpes virus that infects many people worldwide, CMV has been found in up to 10-15% of GBS cases. Epstein-Barr virus (EBV): The virus responsible for infectious mononucleosis (glandular fever) can also trigger an immune response leading to GBS. HIV (Human Immunodeficiency Virus): Some cases of GBS have been linked to early HIV infection. Zika virus: Regions affected by Zika outbreaks have shown a significant increase in GBS cases, suggesting a strong link between Zika infection and the syndrome. SARS-CoV-2 (COVID-19): Reports suggest that GBS can be a neurological complication of COVID-19, although the exact mechanism is still under research.[19-22]

VII. DIAGNOSIS:

Clinical Evaluation and Patient History:
Symptoms Assessment:

A detailed history and neurological examination are crucial in diagnosing GBS. The hallmark symptoms include: Progressive Muscle Weakness: Typically begins in the lower extremities and ascends to involve the upper limbs, face, and respiratory muscles. Weakness usually peaks within 2-4weeks. Some patients experience facial weakness or bulbar involvement (difficulty swallowing and speaking).Loss of Deep Tendon Reflexes (Areflexia or Hyporeflexia): Reflexes are diminished or absent in affected limbs. Sensory Symptoms and feet. Autonomic Dysfunction (in Severe Cases): Abnormal heart rate (tachycardia or bradycardia), blood pressure fluctuations (hypertension or hypotension), gastrointestinal

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 138-144 www.ijprajournal.com ISSN: 2456-4494

dysfunction.: Tingling, numbness, or burning sensations (paresthesia), often in the hands.

History of Preceding Events:

In about 60-70% of cases, GBS is preceded by: Recent infections (1-4 weeks before onset): Campylobacter jejuni (most common bacterial trigger), Cytomegalovirus (CMV), Epstein- Barr Virus (EBV), Mycoplasma pneumoniae, Influenza virus. Vaccination or Surgery: Some cases are associated with influenza, COVID-19, or rabies vaccines.

Diagnostic Tests for GBS:

Nerve Conduction Studies (NCS) & Electromyography (EMG) Purpose:

Assess nerve function and classify GBS subtypes (AIDP, AMAN, AMSAN). Findings: Slowed conduction velocity, conduction block, and prolonged F-wave latencies suggest demyelination. Reduced compound muscle action potentials (CMAPs) suggest axonal involvement.

Lumbar Puncture (Cerebrospinal Fluid Analysis):

Purpose: Helps confirm the diagnosis by detecting albumin cytological dissociation (increased CSF protein with normal white blood cell count). Findings: Elevated CSF protein (>0.45 g/L) without pleocytosis (increased WBCs).CSF protein levels usually rise. within 1-2 weeks of symptom onset.

Blood Tests:

Complete Blood Count (CBC): To rule out infections. Autoimmune Panel: Checks for markers of auto immune conditions. Serology for Campylobacterjejuni, CMV,EBV:

Identifies recent infections. Anti-ganglioside Antibody Testing: Detects antibodies againstGM1,GD1a, or GQ1b, which are present in Miller-Fisher Syndrome (MFS).

MRI of the Spine with Contrast Purpose:

Helps differentiate GBS from other neurological disorders such as transverse myelitis, spinal cord Compression, or acute flaccid myelitis. Findings: Nerve root enhancement in the cauda equina region (seen in some GBS patients).

Differential Diagnosis:

Several conditions mimic GBS, making differential diagnosis crucial. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Similar but progresses over months rather Than days/week Myasthenia Gravis (MG): Muscle weakness worsens with activity (fatiguability), normal reflexes. Transverse Myelitis: Spinal cord MRI shows inflammation, sensory level present. Botulism: Descending paralysis (opposite of GBS), pupillary involvement. Poliomyelitis: Asymmetric paralysis, fever, and meningeal signs.

Advanced Diagnostic Approaches:

Pulmonary Function Tests (PFTs):

Forced Vital Capacity (FVC) <15-20 mL/kg suggests respiratory failure risk. Used to the need for mechanical ventilation.

Autonomic Function Tests:

Tests for heart rate variability, blood pressure changes, and sweat responses to assess autonomic Involvement.

Biomarkers and Genetic Testing:

Emerging research is exploring cytokine levels, neurofilament light chains, and genetic markers for better diagnosis.[23-26]

VIII. TREATMENT:

Plasmapheresis (Plasma Exchange, PE):

Removes harmful antibodies from the blood.
It works best if taken during the first two weeks of symptoms.

Intravenous Immunoglobulin (IVIg):

High-dose donor antibodies that block harmful immune responses. Preferred over plasmapheresis due to easier administration.

Supportive Care:

Ventilation support if breathing muscles are affected.
Physical therapy to keep muscles strong and avoid problems.

IX. NEW AND EMERGING TREATMENTS:

ANX005 (C1q-Blocking Antibody by Annex on Biosciences):

Showed a 2.4-fold improvement in disability scores within 8 weeks. Reduced the need for artificial ventilation and improved muscle strength. FDA has granted fast-track and orphan drug designations for further development.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 138-144 www.ijprajournal.com ISSN: 2456-4494

Eculizumab (Monoclonal Antibody):

Originally approved for blood disorders, now being tested for GBS. Works by inhibiting the complement system to prevent nerve damage. Currently in Phase II clinical trials.

Imlifidase+IVIg (by Hansa Biopharma):

Enzyme-based treatment that removes harmful IgG antibodies. Patients recovered the ability to walk independently in 16 days-6weeks earlier than standard IV Ig-only treatment.[27-29]

X. PREVENTION:

Triggers and Causes of GBS:

Infections as the Leading Trigger:

Bacterial: Campylobacter jejuni, Mycoplasma pneumoniae, Helicobacter pylori. Viral: Influenza, Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Zikavirus, SARS-CoV-2 (COVID-19).

Vaccination-Related Triggers:

Some vaccines (influenza, COVID-19) have a rare link to GBS but infections pose a higher risk.

Surgery and Trauma:

GBS can result from immunological reactions brought on by recent surgeries or injuries.

Genetic and Autoimmune Factors:

Individuals with autoimmune diseases like lupus are at higher risk.

Infection Prevention and Hygiene Practices:

Preventing Campylobacter jejuni Infections Cook poultry thoroughly, avoid raw foods, prevent cross-contamination, wash hands, drink pasteurized milk.

Preventing Viral Infections Wash hands frequently, avoid contact with sick individuals, maintain respiratory hygiene.

Strengthening the Immune System Against Infections

Nutrition: Vitamin C (oranges, peppers), Zinc (nuts, beans), Antioxidants (leafy vegetables), Probiotics (yogurt).

Exercise: 30 minutes daily physical activity. Stress Management: Meditation, proper sleep (7-9 hours). Vaccination Considerations.

Influenza and COVID-19 Vaccines:

Rare cases of GBS have been reported, but risk from actual disease is higher. Safe Vaccination Practices Inform doctors of GBS history, follow vaccination schedules, monitor for symptoms.

Early Diagnosis and Medical Attention:

Recognizing Early Symptoms of GBS: Tingling, muscle weakness, difficulty walking, severe cases involve breathing/swallowing issues.

Immediate Medical Response:

Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIG) for immune system regulation.

Avoiding Certain Medications and Toxins:

Medications to Be Cautious About Fluoroquinolone antibiotics, excessive NSAIDs use. Reducing Exposure to Environmental Toxins. Avoid pesticides, reduce alcohol and tobacco use.

Special Considerations for High-Risk Groups:

Individuals with a History of GBS. Avoid unnecessary vaccinations, regular checkups. People with Autoimmune Disorders. Manage conditions like lupus carefully.[30-32]

XI. PROGNOSIS:

Recovery Outcomes:

Full Recovery (60-80%): Most recover within 6 months to 1 year.

Partial Recovery (10-20%): Some have residual weakness or neurological deficits. Severe Disability (5-10%): Long-term complications like paralysis may persist.

Mortality Rate (4-7%): Due to respiratory failure or cardiac complications, though rare with modern care.

Factors Affecting Prognosis:

Positive Prognostic Factors:

Younger age
Mild symptoms at on set
Early treatment (IVIG/plasmapheresis) No need for mechanical ventilation.

Negative Prognostic Factors:

Older age (over fifty years) At the beginning, severe weakness
Rapid symptom progression (<7 days) Need for mechanical ventilation
Axonal nerve damage (AMAN, AMSAN) Recovery Timeline.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 138-144 www.ijprajournal.com ISSN: 2456-4494

Time Period Recovery Progress:

0-4 Weeks |Peak weakness, treatment starts 1-3 Months Initial improvement, 3-6 Months Significant recovery, 6-12 Months Most regain normal function, 1-2 Years Residual symptoms may persist.[33-36]

XII. COMPLICATIONS:

Respiratory Complications:

Respiratory Muscle Paralysis: 30% of GBS patients may require mechanical ventilation due to respiratory failure.

Aspiration Pneumonia:

Weak throat muscles can lead to food or saliva entering the lungs.

Atelectasis (Lung Collapse): Due to poor chest expansion and mucus build up.

Cardiovascular Complications:

Blood Pressure Fluctuations: Hypertension or Hypotension due to autonomic instability.

Irregular Heart Rhythms(Arrhythmias):

Brady cardiaor Tachycardia, increasing the risk of cardiac arrest.

Orthostatic Hypotension: Sudden drop in BP when standing up, causing dizziness.

Neurological Complications:

Chronic Neuropathic Pain:

Up to 80% of patients experience burning or tingling nerve pain. Residual Weakness & Paralysis: 15-20% of patients experience persistent weakness. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Musculoskeletal Complications:

Muscle Wasting (Atrophy):

Long-term immobility causes muscle shrinkage.

Joint Contractures & Stiffness: Due to prolonged paralysis, requiring physical therapy.

Deep Vein Thrombosis (DVT) & Pulmonary Embolism(PE):

Blood clot formation due to immobility.

Psychological & Cognitive Complications:

Depression & Anxiety: Due to long-term recovery and dependency on others.

PTSD: Commonin ICU-admitted patients who required ventilation.

Cognitive Issues (Rare): Memory problems and difficulty concentrating.

Gastrointestinal & Urinary Complications:

Bowel Dysfunction, Constipation due to autonomic dysfunction,

Bladder Dysfunction: Urinary retention or in continence, Malnutrition & WeightLoss, Dysphagia in severe cases may require a feeding tube.[37-40]

XIII. SUMMARY AND CONCLUSION:

GBS remains a neurological emergency requiring timely diagnosis and multidisciplinary management. Although most patients recover, some may experience long-term disability, underscoring the need for ongoing research and improved treatment protocols. With early intervention, immunotherapy, and supportive care, the majority of patients can regain independence and lead a normal life.

REFERENCES:

[1]. National Institute of Neurological Disorders and Stroke (NINDS) – Information on causes, symptoms, and treatment options for GBS.

[2]. World Health Organization (WHO)– Overview of GBS and its association with infections.

[3]. Mayo Clinic–Detailed explanation of symptoms, risk factors, and management of GBS.

[4]. Centers for Disease Control and Prevention (CDC)–Insights on GBS, its connection to infections, and immunization safety.

[5]. PubMed and Research Articles –Scientific studies on thepathophysiology and treatment approaches for GBS.If you need specific citation styles .

[6]. Willison,H.J.,Jacobs,B.C.,&vanDoorn,P.A.(2016).Guillain-Barrésyndrome.The Lancet, 388(10045), 717-727.

[7]. Yuki,N.,&Hartung,H.P.(2012).Guillain-Barrésyndrome.NewEnglandJournalof Medicine, 366(24), 2294-2304.

[8]. Kuwabara, S.(2004).Guillain-Barrésyndrome: Epidemiology,pathophysiology, and management. Drugs, 64(6), 597-610.

[9]. Yuki N, Hartung HP.'Guillain-Barre Syndrome 'N Engl JMed.2012.

[10]. Willison HJ, Jacobs BC, van Do'GBS Review' Lancet Neurol.2016 orn PA.

[11]. CDC & WHO Reports on GBS Epidemiology.

[12]. Hughes, R. A., & Cornblath, D. R. (2005). 'Guillain-B arre syndrome.' The Lancet, 366(9497), 1653-1666.

[13]. Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). 'Guillain-Barre syndrome.' Nature Reviews Disease Primers, 2, 16018.
[14]. Yuki, N.,& Hartung, H.P.(2012).'Guillain-Barre syndrome. 'New England Journal of Medicine, 366(24), 2294-2304.
[15]. National Institute of Neurological Disorders and Stroke(NINDS)-Guillain-Barré Syndrome.
[16]. Mayo Clinic-Guillain- Barré Syndrome Overview.
[17]. World Health Organization (WHO).
[18]. Barré Syndrome-Johns Hopkins Medicine.
[19]. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barresyndrome. The Lancet. 2016; 388(10045):717-727.
[20]. YukiN, Hartung HP.Guillain-Barresyndrome. NEngl JMed.2012;366(24):2294-2304.
[21]. ShahrizailaN,LehmannHC,KuwabaraS.Guillain-Barresyndrome.TheLancet. 2021;397(10280):1214-1228.
[22]. Wakerley BR, Uncini A, YukiN.Guillain-Barre and Miller Fisher syndromes new diagnostic classification. Nature Reviews Neurology. 2014;10(9):537-544.
[23]. Willison HJ, Jacobs BC, van Doorn PA Guillain-Barré syndrome. Lancet. 2016; 388 (10045): 717-727.
[24]. Hughes RA, Cornblath DR. Guillain-Barrésyndrome.Lancet.2005;366(9497):16531666.
[25]. Yuki N, Hartung HP.Guillain-Barrésyndrome. NEngl JMed.2012;366(24):2294-2304.
[26]. Wijdicks EF, Klein CJ. Guillain-BarréSyndrome.Mayo ClinProc.2017;92(3):467-479.
[27]. "ANX005 trial results and FDA fast-track designation, "Clinical Trials Update,2024.
[28]. "Break through treatment for Guillain-Barré Syndrome: Eculizumab Phase II Trials," MCTLaw, 2024.
[29]. "Hansa Biopharma announces success in GBS trial with Imlifidase," Clinical Trials Arena, 2024.
[30]. Willison HJ, Jacobs BC, vanDoorn PA.Guillain-Barrésyndrome.Lancet.2016.
[31]. YukiN, Hartung HP.Guillain-BarréSyndrome.NEnglJMed.2012.
[32]. National Institute of Neurological Disorders and Stroke (NINDS). Guillain-Barré Syndrome Fact Sheet.
[33]. National Institute of Neurological Disorders and Stroke (NINDS)-Guillain-Barré Syndrome: www.ninds.nih.gov.
[34]. Mayo Clinic-Guillain-Barré Syndrome Treatment & Prognosis: www.mayoclinic.org.
[35]. American Physical Therapy Association(APTA)-GBS Rehabilitation Guidelines.
[36]. YouTube:Physio therapy and Exercise Tutorials for GBS Recovery.
[37]. YukiN, Hartung HP."Guillain- Barré Syndrome."NewEngl and Journal of Medicine,2012.
[38]. Willison HJ, Jacobs BC, van Doorn PA."Guillain-Barré Syndrome."Lancet,2016.
[39]. Sheikh KA, Cornblath DR. "Neurological complications of GBS: Clinical review." Journalof Neurology, 2020.
[40]. National Institute of Neurological Disorders and Stroke (NINDS), Guillain-Barré Syndrome Fact Sheet, 2021.